Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Ardizzoni

Showing results (51-60 of 370) with videos related to

Pageof 37
Sort By:
Critical Reviews in Oncology/Hematology|March 23, 2021
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategyAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2021
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanomaAlessandro Di Federico, Daria Maria Filippini, Francesca Sperandi, et al.
Vaccines|January 7, 2021
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBaseMilo Gatti, Emanuel Raschi, Ugo Moretti, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 4, 2015
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patientsFrancesco Facchinetti, Raffaella Aldigeri, Rosalia Aloe, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2002
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)Editta Baldini, Andrea Ardizzoni, Tiziana Prochilo, et al.
British Journal of Haematology|February 12, 2009
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acidsAntonino Musolino, Michele Panebianco, Enrico Zendri, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2020
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world dataFilippo G Dall'Olio, Ilaria Maggio, Maria Massucci, et al.
Future Oncology (London, England)|January 14, 2026
Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panelAndrea Ardizzoni, Diego Cortinovis, Bruno Gori, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?Filippo Gustavo Dall'Olio, Stefano Brocchi, Maria Massucci, et al.
Targeted Oncology|July 30, 2020
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from PharmacovigilanceEmanuel Raschi, Milo Gatti, Francesco Gelsomino, et al.
Pageof 37

Showing results (51-60 of 370) with videos related to

Sort By:
Pageof 37
Critical Reviews in Oncology/Hematology|March 23, 2021
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategyAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2021
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanomaAlessandro Di Federico, Daria Maria Filippini, Francesca Sperandi, et al.
Vaccines|January 7, 2021
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBaseMilo Gatti, Emanuel Raschi, Ugo Moretti, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 4, 2015
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patientsFrancesco Facchinetti, Raffaella Aldigeri, Rosalia Aloe, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2002
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)Editta Baldini, Andrea Ardizzoni, Tiziana Prochilo, et al.
British Journal of Haematology|February 12, 2009
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acidsAntonino Musolino, Michele Panebianco, Enrico Zendri, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2020
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world dataFilippo G Dall'Olio, Ilaria Maggio, Maria Massucci, et al.
Future Oncology (London, England)|January 14, 2026
Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panelAndrea Ardizzoni, Diego Cortinovis, Bruno Gori, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?Filippo Gustavo Dall'Olio, Stefano Brocchi, Maria Massucci, et al.
Targeted Oncology|July 30, 2020
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from PharmacovigilanceEmanuel Raschi, Milo Gatti, Francesco Gelsomino, et al.
Pageof 37